Figure 2. Mortality risk with SARS–CoV-2 convalescent plasma versus control by age, reproductive number, projected efficacy of intervention, and time.

Fatalities from SARS-CoV-2 were estimated by age groups assuming moderate and high R₀ scenarios over 100 (d = 100) or 365 (d = 365) days. We calculated the number of averted deaths from treatment per 1,000 individuals for a range of treatment efficacy: (A) 25%, (B) 50%, and (C) 75%. We estimated these values using simulated incidence values from multiple runs of the transmission model. Results are shown for the mean (shown as a point) and 95% quantile. The estimated probability of death from a plasma transfusion was conservatively set at 41/3.6 million (solid black vertical line) (49).